Pharma & Biotech

BioNxt Solutions has formally initiated the commercial phase for its sublingual drug delivery platform, marking a significant corporate milestone announced...

In a counterintuitive market reaction, Ocugen's stock price declined significantly following the announcement of encouraging 12-month data from its Phase...

A significant regulatory warning from the U.S. Food and Drug Administration (FDA) has triggered a sharp sell-off in ImmunityBio shares....

A surge in institutional buying activity is placing a traditional healthcare conglomerate firmly on the radar of major market players....

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical company faces a...

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational improvements but also...

As Humacyte prepares to release its full-year 2025 financial results, the biotechnology firm finds its stock trading at a historic...

Despite reporting operational headway and a narrower-than-expected quarterly loss, Talphera's stock experienced significant selling pressure. The market's focus appears fixed...

Lexaria Bioscience is positioning its proprietary DehydraTECH technology as a potential solution to a critical problem plaguing popular weight-loss and...

In a surprising market reaction, shares of biotechnology firm Ocugen experienced a significant sell-off this week, even as the company...